Summary Overexpression of transforming growth factor-4 isoforms (TGF-f1, -P2, -,B3) has been previously reported in human melanoma cell lines and tumours. The aim of the present study was to evaluate the plasma levels of TGF-f isoforms in melanoma patients. Significantly elevated levels of TGF-,1l (4.2 x the controls, P= 0.0094) and of TGF-,2 (1.5 x the controls, P= 0.012) but not of TGF-13 were measured in patients with disseminated but not locoregional melanoma. These results indicate systemic circulation of potentially immunosuppressive peptides of the TGF-P family in end-stage melanoma patients.
-P2, -[3) are members of a superfamily of multifunctional polypeptides that control cell growth and differentiation (Massague, 1990) . TGF-[3 may promote angiogenesis and wound healing and also acts as a potent immunosuppressive factor by inhibiting proliferation of bone marrow progenitor cells, of T-and B-cell lineages as well as their functions, including B-cell immunoglobulin synthesis, lymphokine-activated killer (LAK) cytotoxicity, natural killer (NK) cytotoxicity and T-cell cytotoxicity (Wahl et al, 1989 ). Overexpression of TGF-P and loss of growth inhibition have been described in melanoma cell lines in vitro (MacDougall et al, 1993; Krasagakis et al, 1994; Rodeck et al, 1994) . In vivo, TGF-f31 mRNA has been detected in metastatic nodules, and increased TGF-12 mRNA expression has been reported in deep invasive primary tumours (Luscher et al, 1994; Reed et al, 1994) .
Furthermore, increased expression of TGF-,B1, -[2 and -[3 protein was observed in lesions of invasive primary melanomas and in metastatic nodules compared with melanocytes, and of TGF-132 and -13 in lesions of melanoma metastases compared with naevi (Van Belle et al, 1996) . These results suggest a relation of TGF-3 isoforms with tumour progression in situ and raise the question whether patients with malignant melanoma have elevated circulating levels of TGF-[ isoforms and whether an association occurs with tumour progression. We therefore determined the plasma levels of A total of 13 of the patients had locoregional disease (four with primary tumour alone and nine with regional lymph node involvement) and 12 had distant metastatic spread. For the assays, the plasma was treated with 2.5 N acetic acid/10 M urea followed by 2.7 N sodium hydroxide/I M N-(-2-hydroxyethyl)-piperazine-N'-(2-ethanesulphonic acid) (Hepes) for assessment of total plasma TGF-13 isoforms (active and latent forms). measured with commercially available enzyme-linked immunosorbent assays (ELISAs, R&D Systems, Minneapolis, MN, USA); for TGF-[3, a sandwich ELISA technique using goat polyclonal anti-TGF-P3 antibody (R&D Systems) as the coating reagent has been used. Plasma samples, if necessary diluted with phosphate-buffered saline (PBS, Biochrom, Berlin) and 0.1% bovine serum albumin (BSA, Sigma, Deisenhofen, Germany), were added to 96-well microtitre antibodycoated plates and incubated for 90 min. After several washes with washing buffer (WB), which was PBS with 0.5% BSA and 0.2% Triton X-100, the second antibody (rabbit polyclonal antibody detecting an epitope corresponding to amino acids 350-375 mapping at the carboxy terminus of the precursor form of human TGF-P3) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), was added for 60 min. After repeated washes with WB, the third antibody (horseradish peroxidase conjugated goat anti-rabbit IgG F(AB')2 fraction from Medac Diagnostika, Hamburg) was applied for 60 min. After several washes with WB, the chromogenic substrate O-diphenylenediamine dihydrochloride (Sigma) was added to the wells. After 20 min the reaction was stopped usingTGF-f plasma levels in melanoma patients 1493 
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Statistical analysis was performed with SPSS package and significance levels were corrected for multiple tests in pairwise comparisons between more than two groups (Conover procedure). A P-value of 0.017 is consistent for an overall type I error of 0.05 when comparing controls, locoregional melanoma and disseminated melanoma patients, and the P-value remains 0.05 when comparing controls with all melanoma patients.
RESULTS
The median plasma TGF-[1 level for all melanoma patients examined was 13.900 pg ml-' (25th percentile, 8.020 pg ml-'; 75th percentile, 36.400 pg ml-1) and did not differ significantly from that found in controls (median, 8.150 pg ml-'; 25th percentile, 3.950 pg ml-'; 75th percentile, 18.890 pg ml-'; P = 0.080, Mann-Whitney test). However, when assessed according to subgroups, the TGF-[1 levels measured were significantly higher in patients with distant melanoma metastasis than in controls (median, 34.500 pg ml-'; 25th percentile, 9.850 pg ml-'; 75th percentile, 46.080 pg ml-'; P = 0.0094; see Figure 1 ). No statistical difference was found between patients with locoregional melanoma and controls. Also, the plasma levels of TGF-j32 (median, 193 pg ml-'; 25th percentile, 163 pg ml-'; 75th percentile, 253 pg ml-'; controls) were found significantly elevated in all disconcerted melanoma patients (median, 281 pg ml-'; 25th percentile, 208 pg ml-'; 75th percentile, 307 pg ml-'; P = 0.031), particularly in patients with distant melanoma metastasis (median, 285 pg ml-'; 25th percentile, 239 pg ml-'; 75th percentile, 363 pg ml-'; P = 0.012). Plasma TGF-[B2 in patients with locoregional involvement did not differ statistically from the control values (see Figure 1) . The plasma levels of TGF-[3 were found unaltered in melanoma patients (median, 290 pg ml-'; 25th percentile, 0 pg ml-'; 75th percentile, 847 pg ml-') vs controls (median, 189 pg ml-'; 25th percentile, 0 pg ml-'; 75th percentile, 824 pg ml-'; P = 0.619), irrespective of the disease stage. 62.5 pg ml'. For evaluating cross reactivity with other cytokines, ELISAs were performed using TGF-J3 as standard, and assessed the possible cross-immunoreactivity of the combination of the antibodies with different dilutions (0-50 ng ml-') of other cytokines. The ELISA did not show detectable cross-reactivity to dilutions of TGF-[I and TGF-12 or to other cytokines, including epidermal growth factor, TGF-a, nerve growth factor, basic fibroblast growth factor, platelet-derived growth factor, interleukin (IL)-1 , IL-2, IL-3, IL-4, IL-5, IL-6, tumour necrosis factor (TNF)-a and TNF-[ at a tested range of 50 ng ml-'.
DISCUSSION
The source of elevated plasma levels of TGF-,31 and TGF-[B2 is possibly tumour derived. TGF-11 was shown to be the major secreted isoform in vitro, although in some cases TGF-133 was found; small amounts of TGF-[32 were specifically secreted by melanoma cells and not by benign melanocytes (Krasagakis et al, 1997 (Ivanovic et al, 1995; Tsushima et al, 1996) causatively involved in the impairment of the immune system in melanoma patients with advanced tumour dissemination. Indeed, several lines of evidence suggest a role for tumour-derived TGF-[3-mediated immunosuppression. A highly immunogenic tumour transfected with a murine TGF-j1 cDNA escaped immune surveillance in mice, and TGF-[2 has been identified as the T-cell suppressor factor of human glioblastoma (de Martin et al, 1987; Torre-Amione et al, 1990) . Furthermore, treatment of mice with anti-TGF-[B antibodies inhibited growth of human breast cancer cells by enhancing spleen NK-cell activity (Arteaga et al, 1993) . In addition, B16 melanoma growth and metastasis in vivo was inhibited by treatment of mice with anti-transforming growth factor beta antibody and interleukin 2 (Wojtowicz-Praga et al, 1996) , indicating that therapeutic interventions for blocking systemic TGF-[B overexpression should be taken under further consideration.
